Sunday, October 17

US FDA approves AbbVie’s migraine prevention drug

Article content

AbbVie Inc said on Tuesday the US health regulator approved its once-daily oral medicine for the preventive treatment of migraine in adults, adding a third drug to the drugmaker’s bank of products for severe headaches.

The drugmaker acquired the medicine, Qulipta, as part of its $63 billion deal for Allergan, along with anti-wrinkle and chronic migraine treatment Botox and acute migraine drug Ubrelvy. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)

Leave a Reply

Your email address will not be published. Required fields are marked *